Business Context and Reporting Period
TriSalus Life Sciences, Inc. (TLSI) filed a Current Report on Form 8-K dated February 19, 2026. The filing announces the entry into a material definitive underwriting agreement for a public offering of common stock.
Key Financial Metrics and Transaction Details
- Offering Size: 9,756,100 shares of common stock at $4.10 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 1,463,415 additional shares.
- Underwriting Discount: 6.0% of the offering price per share.
- Estimated Net Proceeds: Approximately $37.0 million (without over-allotment) or $42.64 million (with full over-allotment exercise).
- Use of Proceeds: General corporate purposes, including capital expenditures, working capital, and general and administrative expenses.
- Expected Closing Date: On or about February 23, 2026.
Material Changes and Agreements
The primary material change is the execution of the Underwriting Agreement with Lake Street Capital Markets, LLC. The Company, along with its officers, directors, and a certain securityholder, has agreed to a 90-day lock-up period, prohibiting the sale or disposal of securities without the underwriters' written consent.
Guidance, Risks, and Contingencies
The filing does not provide specific financial guidance or outlook beyond the intended use of proceeds. The transaction is subject to customary closing conditions. The Underwriting Agreement includes customary representations, warranties, and indemnification provisions for liabilities arising under the Securities Act of 1933.
Investor Verification Checklist
- Verify the final closing date and whether the over-allotment option was exercised.
- Confirm the actual net proceeds received after deducting all offering expenses.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific termination provisions.
- Monitor the 90-day lock-up expiration date for potential selling pressure from insiders.
- Check subsequent filings for updates on the deployment of capital for stated corporate purposes.